<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111529">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01652027</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-11-0202</org_study_id>
    <secondary_id>HSC-MS-11-0202</secondary_id>
    <nct_id>NCT01652027</nct_id>
  </id_info>
  <brief_title>Hemophilia Inhibitor Previously Untreated Patient Study</brief_title>
  <acronym>HIPS</acronym>
  <official_title>Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rho, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemophilia A is a congenital bleeding disorder caused by deficiency of factor VIII (FVIII)
      and is treated by replacement therapy with FVIII concentrate. Approximately 30% of people
      with severe hemophilia A develop neutralizing antibodies, called FVIII inhibitors, which
      interfere with the function of FVIII concentrates. The reason that some, but not all, people
      with severe hemophilia A develop inhibitors is incompletely understood. Understanding
      individual and environmental risk factors is important to be able to prevent and possibly
      treat inhibitors. This study will look at individual and treatment characteristics in babies
      with severe hemophilia A who have not yet received treatment with FVIII (called Previously
      Untreated Patients, or PUPS). Subjects in the study will be asked to provide diaries of
      treatments, medications, and illnesses. Treatment will be directed by the subjects'
      physician, but all subjects will receive Advate, a third-generation recombinant FVIII
      product. Subjects will have blood drawn for laboratory tests, which include studies of the
      immune system and genetic studies of the FVIII mutation, before and 7-9 days after the first
      treatment with FVIII, and 5 days (+/-2 days) after the 5th, 10th, 20th, 30th, 40th, and 50th
      days of treatment with FVIII (exposure days). The duration of the study will be first 50
      treatments or 3 years, whichever comes first.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of FOXP3-positive T regulatory cells in the circulation</measure>
    <time_frame>50 exposure days to FVIII or 3 years, whichever comes first</time_frame>
    <description>FoxP3(a protein involved in immune system responses)-positive T regulatory cells in the circulation will be compared before and after exposure to FVIII.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FVIII-specific T-cells</measure>
    <time_frame>50 exposure days to FVIII or 3 years, whichever comes first</time_frame>
    <description>FVIII-specific T-cells will be compared before and after exposure to FVIII</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Previously Untreated Patients with Hemophilia A</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FVIII concentrate</intervention_name>
    <description>usual treatment as directed by treating physician</description>
    <arm_group_label>Previously Untreated Patients with Hemophilia A</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples, lymphocyte cell lines, Genomic DNA, RNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe hemophilia A who have not previously been treated with Factor VIII
        concentrates.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe hemophilia A with FVIII activity &lt; 1% normal

          -  Weight &gt; 3.5 kg at the time of baseline study evaluation

          -  Informed consent, approved by appropriate Institutional Review Board/Independent
             Ethics Committee, has been administered, signed, and dated

        Exclusion Criteria:

          -  Prior exposure to clotting factor concentrates or blood products

          -  Other chronic disease

          -  Currently participating in another investigational drug study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Santagostino, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maggiore Hospital and University of Milan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah L. Brown, M.D.</last_name>
    <phone>713-500-8360</phone>
    <email>deborah.brown@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharyne Donfield, PhD</last_name>
    <phone>919-595-6225</phone>
    <email>sharyne_donfield@rhoworld.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Meeks, M.D.</last_name>
      <phone>404-727-1608</phone>
      <email>shannon.meeks@choa.org</email>
    </contact>
    <contact_backup>
      <last_name>David Hellwedge</last_name>
      <phone>404-785-4677</phone>
      <email>david.hellwege@emoryhealthcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Shannon Meeks, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia and Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Shapiro, M.D.</last_name>
      <phone>317-871-0000</phone>
      <email>ashapiro@ihtc.org</email>
    </contact>
    <contact_backup>
      <last_name>Erin Wiles</last_name>
      <phone>317-871-0011</phone>
      <phone_ext>269</phone_ext>
      <email>ewiles@ihtc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Shapiro, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vlad Radulescu, MD</last_name>
      <phone>859-257-6033</phone>
      <email>vcradu2@email.uky.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Samuelson</last_name>
      <phone>859-257-1000</phone>
      <email>jennifer.samuelson@uky.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Vlad Radulescu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Kruse-Jarres, M.D.</last_name>
      <phone>504-988-3562</phone>
      <email>rkruseja@tulane.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carol DeKernion</last_name>
      <phone>504-988-3566</phone>
      <email>cdekern@tulane.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rebecca Kruse-Jarres, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine McGuinn, MD</last_name>
      <phone>212-746-3400</phone>
      <email>cam9061@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Fraustina Hsu</last_name>
      <phone>212-746-4126</phone>
      <email>frh2005@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Catherine McGuinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Monahan, M.D.</last_name>
      <phone>919-843-4984</phone>
      <email>paul_monahan@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robin Kellerman</last_name>
      <phone>919-0843-3942</phone>
      <email>roberta_kellerman@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Monahan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Gruppo, M.D.</last_name>
      <phone>513-636-8617</phone>
      <email>ralph.gruppo@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Justin Pennington</last_name>
      <phone>513-803-4617</phone>
      <email>justin.pennington@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ralph Gruppo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oregon</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Recht, MD</last_name>
      <email>rechtm@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>susan Lattimore</last_name>
      <phone>503 418 4495</phone>
      <email>lattimor@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Recht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hemophilia Center of Western Pennsylvania</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Ragni, M.D.</last_name>
      <phone>412-209-7280</phone>
      <email>ragni@dom.pitt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Judith Kadosh</last_name>
      <phone>412-209-7263</phone>
      <email>JKadosh@itxm.org</email>
    </contact_backup>
    <investigator>
      <last_name>Margaret Ragni, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Texas Comprehensive Hemophilia Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janna Journeycake, MD</last_name>
      <phone>214-730-5437</phone>
      <email>janna.journeycake@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anna Winborn</last_name>
      <phone>214-456-8185</phone>
      <email>anna.winborn@childrens.com</email>
    </contact_backup>
    <investigator>
      <last_name>Janna Journeycake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Yee, MD</last_name>
      <phone>832-822-4861</phone>
      <email>DLYEE@txch.org</email>
    </contact>
    <contact_backup>
      <last_name>Margaret Nagel</last_name>
      <phone>832-824-1538</phone>
      <email>menagel@txch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Donald Yee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center-Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah L. Brown, M.D.</last_name>
      <phone>713-500-8360</phone>
      <email>deborah.brown@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Madeline Cantini, BSN</last_name>
      <phone>713-500-8377</phone>
      <email>madeline.cantini@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deborah L Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Hemophilia and Thrombosis Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Yaish, MD</last_name>
      <phone>801-662-4700</phone>
      <email>Hassan.Yaish@imail.org</email>
    </contact>
    <contact_backup>
      <last_name>Tiffanie Hales</last_name>
      <phone>801-213-3367</phone>
      <email>Tiffanie.Hales@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hassan Yaish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Male, MD</last_name>
      <phone>43 1 40400 2110/3232</phone>
      <email>christoph.male@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Eva Wissmann</last_name>
      <phone>43 1 40400 3488</phone>
      <email>eva.wissmann@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Christoph Male, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angelo Bianchi Bonomi Hemophilia &amp; Thrombosis Center</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Santagostino, MD</last_name>
      <phone>39 02 5503 5308</phone>
      <email>Elena.Santagostino@policlinico.mi.it</email>
    </contact>
    <contact_backup>
      <last_name>Vega Rusconi</last_name>
      <phone>39 02 5503 3623</phone>
      <email>vega.rusconi@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Elena Santagostino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emma Children's Hospital AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Fijnvandraaat, M.D.</last_name>
      <phone>31 20 566 2727</phone>
      <email>c.j.fijnvandraat@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Samanth Gouw, M.D.</last_name>
      <phone>31 20 5662727</phone>
      <email>s.c.gouw@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Karin Fijnvandraat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Malmo Centre for Thrombosis and Haemostasis</name>
      <address>
        <city>Malmo</city>
        <zip>Se-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Klintman, M.D.</last_name>
      <phone>46 40 331952</phone>
      <email>jenny.klintman@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Marcus Ljungksvist</last_name>
      <phone>46 046 222 0000</phone>
      <email>marcus.ljungkvist@med.lu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Jenny Klintman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 27, 2016</lastchanged_date>
  <firstreceived_date>June 3, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Deborah Brown</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>FVIII inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
